Not all patients require maximum dosing, and some achieve optimal results at intermediate doses
It works by mimicking natural hormones in your body that control hunger, fullness, and blood sugar levels
Their remarkable efficacy in reducing both body weight and obesity-related comorbidities, including CVD and overall mortality ( Indeed, pharmacotherapy with GLP-1 receptor or dual GIP/GLP-1 receptor agonists in patients with obesity achieves impressive reductions in body weight in the range of 1525% compared with TRE or other nutritional interventions, which are typically in the range of 34% ( Indeed, although long-term monitoring of the adverse effects of anti-obesity medications is still needed, data from clinical trials supports favorable efficacy versus safety profiles and demonstrates significant improvements in several cardiometabolic health parameters ( A mixed strategy incorporating both pharmacotherapy and dietary interventions may offer the most comprehensive and pragmatic approach to obesity and cardiometabolic risk management
More on the trial: medscape.com/viewarticle/ca Continuing tirzepatide helped adults without diabetes maintain far more of their initial weight loss than stopping the drug, with the strongest effect seen in those who stayed on their maximum tolerated dose, according to results from the SURMOUNT-MAINTAIN trial
High heat can break down the medication, while freezing can destroy the proteins inside the injection beyond repair
